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Abstract
Background: Low levels of Cytomegalovirus (CMV) viral load are frequently detected following allogeneic stem cell
transplantation (SCT) and CMV disease may still develop in some allogeneic SCT patients who have negative pp65-
antigenemia (pp65-Ag) or undetectable DNA. Pp65Ag is a sensitive method to diagnose CMV infection. Quantitative
CMV-DNA PCR assay in plasma has been proposed to monitor CMV infection in SCT patients. We evaluated the clinical
utility of pp65Ag and PCR assay in plasma of SCT recipients.
Methods: In a prospective longitudinal study, 38 consecutive patients at risk of CMV infection (donor and/or recipient
CMV seropositive) were weekly monitored for CMV infection by both quantitative CMV-PCR in plasma (COBAS
AMPLICOR CMV MONITOR) and pp65 Ag, during the first 100 days after SCT.
Results: A total of 534 blood samples were simultaneously analysed for pp65Ag and PCR. Overall, 28/38 patients (74%)
had active CMV infection within 100 days from SCT. In 16 patients, CMV was first detected by pp65 Ag alone; in 5
patients by both methods and in 6 by PCR assay alone; one patient had CMV biopsy-proven intestinal disease without
pp65Ag and PCR assays positivity before CMV disease. Overall, three patients developed intestinal CMV disease (7.9%):
one had negative both pp65Ag and PCR assays before CMV disease, one had disease and concomitant positivity of both
methods, while in the remaining patient, only pp65Ag was positive before CMV disease.
Conclusion: Plasma PCR(COBAS AMPLICOR CMV MONITOR) and pp65Ag assays were effective in detecting CMV
infection, however, discordance between both methods were frequently observed. Plasma PCR and pp65Ag assays may
be complementary for diagnosis and management of CMV infection.
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Background
Cytomegalovirus (CMV) infection still causes significant
morbidity and mortality following allogeneic stem cell
transplantation (SCT) [1]. The impact of this infection on
transplantation extends beyond the direct clinical mani-
festations (e.g. pneumonitis, gastrointestinal diseases,
hepatitis, marrow suppression) and includes indirect
effects such as increased incidence of other opportunistic
infections and decreased patient survival [2,3]. Therefore,
prevention and treatment of active CMV infection must be
based on sensitive and reliable diagnostic assays. Pre-
emptive therapy administered on the basis of evidence of
CMV reactivation has become a common strategy in the
treatment of SCT recipients [4,5]. A commonly used test
to detect active CMV infection is the immune-fluorescence
staining of CMV lower matrix protein pp65 (UL83) in
peripheral blood leukocytes (PBL) [6]. In the pp65 anti-
genemia (pp65Ag) assay, the number of CMV positive
cells in the peripheral blood reflects the viral load and
high numbers of pp65 positive cells correlate with CMV
disease [7,8]. A significant threshold is used in transplant
recipients for predicting CMV disease. Clinically relevant
threshold of the number of infected PBL differs among the
different patient populations. Thresholds of more than 10
positive cells/200.000 PBL and >1 or 2 positive cells/
200.000 cells have been suggested to guide pre-emptive
therapy in solid organ and SCT recipients, respectively
[9,10]. Pre-emptive therapy based on pp65 antigen detec-
tion in PBL is associated with a reduction in the incidence
of CMV disease in allogeneic SCT recipients [11]. How-
ever, the antigen based diagnostic test has some disadvan-
tages: low sensitivity for detecting early active CMV
infection or disease that may occur before engraftment
due to the lack of leukocytes during the period of aplasia
(requirement of neutrophil counts >0.5 × 109cells/L) and
low positive predictive value for the occurrence of CMV
gastroenteritis [12,13]. Furthermore, pp65Ag assay
requires processing of the blood samples within few
hours, is time consuming, and cannot be automated.
PCR-based methods have been recently evaluated for
diagnosing and monitoring CMV infection after alloge-
neic SCT [14-16]. However, it remains difficult to evaluate
the exact role of the previously reported PCR assays in
guiding pre-emptive CMV therapy in the allogeneic SCT
recipients, due to differences in the origin of samples
[whole blood, plasma, serum, PBL, peripheral blood
mononuclear cells (PBMC)] and the type of PCR proce-
dures (qualitative versus quantitative) used for monitor-
ing [17-21].
Previous studies showed that the presence of CMV in
plasma or serum is indicative of active viral replication
being associated with a high predictive value for CMV dis-
ease in SCT recipients [22,23] and in HIV-infected
patients [24]. In addition, plasma offers the opportunity
to detect active CMV infection during periods of severe
cytopenia when cell-based assays (PCR on leukocytes and
pp65-antigenemia) perform poorly [25]. However, clini-
cal results of plasma PCR in allogeneic SCT recipients are
still controversial since CMV PCR assays used in clinical
studies have been developed in-house [15,25] and the
methods are not standardized.
There is much interest in the quantification of CMV load
in blood for monitoring and prediction of CMV disease
development and progression. Many studies have shown
that the amount of CMV DNA is significantly associated
with disease development [16,21,23]. However, while evi-
dences indicate that high CMV load is associated with a
higher risk of progression to CMV disease in solid organ
transplant recipients, the association may be less clear for
allogeneic SCT recipients [12]. Further, low levels of CMV
viral load are frequently detected following allogeneic
SCT [16,26] and CMV disease may still develop in some
allogeneic SCT patients who have negative pp65-Ag or
undetectable DNA [1].
In this study, 38 patients were prospectively monitored
for CMV infection during the first 100 days post-SCT. Two
different commercially available assays were simultane-
ously used to compare clinical utility of a cell-based pp-65
Ag test with plasma PCR (COBAS AMPLICOR CMV MON-
ITOR). Pre-emptive therapy, based on a positive pp65Ag
assay result, was administered in all SCT recipients.
Methods
Patients and study design
Between January 2003 and February 2005, 42 consecutive
SCT recipients at risk for CMV infection (donor and/or
recipient CMV seropositive) were included in the study.
Four out of 42 patients were excluded because survived
less than 50 days after transplantation without any evi-
dence of pp65 Ag positive cells and/or CMV-DNA. There-
fore, 38 patients were considered valuable for this study.
Blood samples were tested for CMV by both quantitative
CMV-PCR in plasma and pp65 Ag at weekly intervals and,
on suspicion of CMV infection, from day -7 to day 100
post-transplant.
Patients underwent SCT at the Transplant Unit of S.
Eugenio Hospital, Tor Vergata University, Rome, Italy.
From the time of hospital admission onwards, patients
were given standard prophylaxis for bacterial (levo-
floxacin 500 mg daily p.o.), and fungal (fluconazole at
200 mg twice daily p.o.) infections. Acyclovir at standard
(250 mg/m2 i.v. every 8 hours, or 200 mg four times a
day) or high (500 mg/m2 i.v. every 8 hours, or 800 mg p.o.
four times a day) dose was given for prophylaxis of herpes
simplex virus infections in related or unrelated trans-BMC Infectious Diseases 2006, 6:167 http://www.biomedcentral.com/1471-2334/6/167
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plants, respectively. No patients received prophylactic
intravenous immunoglobulins, ganciclovir, foscarnet, or
cidofovir. The ethic Committee of S. Eugenio Hospital,
Tor Vergata University, Rome approved the study and an
informed written consent was received from each patient.
Patient characteristics are summarized in Table 1.
Criteria for the diagnosis of CMV infection and disease
Cytomegalovirus infection and disease were defined
according to published recommendations [27]. Active
CMV infection was defined as the detection of pp65 anti-
gen in leukocytes and/or the presence of CMV DNA in
plasma. CMV enteritis was defined as the presence of gas-
trointestinal symptoms, findings of macroscopic mucosal
lesions on endoscopy, and demonstration of CMV infec-
tion (by culture, histopathologic testing and immunohis-
tochemical analysis) in biopsy samples taken from colon.
Detection of CMV by PCR alone was considered insuffi-
cient for the diagnosis of CMV intestinal disease.
CMV serology
Serum samples were tested by a commercially available
enzyme linked immunosorbent assay (Delta Biological,
Italy), according to the manufacturer's instructions.
Specimen processing
A 15 ml volume of EDTA-treated blood was collected
from each patient. Ten ml were used for CMV Ag assay and
processed within 4 hours; plasma obtained from the
remaining blood was used for CMV PCR assay.
Virological assays
Pp65 antigen test (Antigenemia assay)
The CMV pp65 antigenemia test was carried out with
commercially available monoclonal antibodies, accord-
ing to the standard protocol [CINA Kit, Argene]. Briefly,
EDTA-treated whole blood samples were fractioned by
dextran-sedimentation and lysis of erythrocytes. Slides
were incubated with monoclonal anti-pp65 [pool of
monoclonal antibodies (1C3+AYM-1), Biosoft, Paris,
France]. The pp65 Ag results were reported as the total
number of positive cells/200.000 PBL examined. All clin-
ical decision regarding pre-emptive antiviral therapy were
based on CMV Ag.
Quantification of CMV-DNA
CMV-DNA was quantified on plasma samples by using
the Cobas Amplicor CMV Monitor, according to the man-
ufacturer's instructions (Roche Molecular Systems). The
dynamic range for quantification is approximately 3 log10
units, with 400 copies as the lower limit of detection.
Preemptive therapy for prevention of CMV disease
Pre-emptive therapy was started at the first detection of
pp65-Ag positive cells (≥ 1 positive cell/200,000 cells).
Plasma CMV DNA results were not considered for clinical
decision making. Antiviral pre-emptive therapy was based
on intravenous infusion of either ganciclovir at 10 mg/Kg/
day or foscarnet at 180 mg/Kg/day for 2 to 3 weeks fol-
lowed by either ganciclovir at 5 mg/Kg/day or foscarnet at
90 mg/Kg/day for 2 to 3 weeks.
Table 1: Clinical characteristics
Characteristics Value
Patients 38
Age, y
Median 41
Range (11–68)
Sex
Male 22
Female 16
Diagnosis
Acute leukemia 16
Lymphoma 6
Multiple myeloma 4
Myelodyspastic syndrome 4
Solid tumor 4
Non neoplastic disorders 3
Chronic lynphocytid leukemia 1
Acute GVHD
0–I 27
II–IV 11
Total body irradiation
Yes 15
No 23
Conditioning regimen
Standard 25
Reduced intensity conditioning 13
Type of transplant
Related 30
Unrelated 8
Hemopoietic reconstitution
Median days of PMN >0.5 × 109/L (range) 16 (11 – 41)
Median days of PLTS >20 × 109/L (range) 15 (9 – 65)
Median days of PLTS >50 × 109/L (range) 18 (11 – 88)
Source of stem cells
Peripheral blood 31
Bone marrow 4
Cord blood 3
Prophylaxis of aGVHD
CyA+MTX 25
CyA+MMF 6
CyA+PDN 4
Other 3
CMV status (donor/recipient)
Positive/positive 26
Negative/positive 10
Positive/negative 2
Deaths 4
GVHD: Graft versus host disease; CyA: Cyclosporin-A; MTX: 
Methotrexate; PDN: Prednisone; CMV: Cytomeglovirus. MMF: 
Micofenolate Mofetil; PMN: Peripheral Mononuclear cells; PLTS: 
PlateletsBMC Infectious Diseases 2006, 6:167 http://www.biomedcentral.com/1471-2334/6/167
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Statistical analysis
The agreement between CMV detection assay was evalu-
ated using the Kappa coefficient. Values of kappa above
0.75 indicate strong agreement; values between 0.40 and
0.75 represent fair to good agreement and value less than
0.40 reflect poor agreement [28].
The mean period of time between transplant and pp65 Ag
or PCR positivity (whichever first occurred) were com-
pared by the Student's t-test. Differences between median
time of disappearance of pp65 Ag or DNA were tested
using Mann-Withney test. After normalization of the
pp65 Ag values by logarithmic transformation (log10), the
correlation between the two test was evaluated with Pear-
son's correlation coefficient. Differences in percentages
were tested using the Fisher's exact test (2-tailed). P-values
less than 0.05 were considered statistically significant.
Results
Clinical outcome
Of the 38 valuable patients, 25 (70%) had active CMV
infection (Table 2), 10 did not develop CMV infection
and 3 developed pathologically diagnosed CMV colitis
(Table 3).
Four of the engrafted patients died within 100 days after
SCT: two for progression of acute myeloid leukemia and
colon carcinoma, respectively; one for acute GVHD and
one for CMV disease associated with acute GVHD.
Detection of CMV by pp65 antigenemia, and by the Cobas 
CMV PCR assays
Overall, 568 blood samples were analysed for pp65Ag
and/or PCR; of the 35 (6.2%) samples obtained from
patients in whom the pp65 Ag assay could not be per-
formed because of the low number of cells (i.e. before
engraftment or during severe neutropenia with absolute
neutrophil counts of less than 200/μl), none was positive
by plasma PCR assay. Of the 534 samples tested simulta-
neously for pp65 Ag and PCR, 31 (5.8%) were positive by
PCR and pp65 Ag, 30 (5.6%) were pp65 Ag positive but
PCR CMV negative, 22 (4.1%) were PCR positive/pp65Ag
negative, and 451 (84.4%) were negative by both assays.
CMV was detected in 83 samples (15%) by a single or
both methods.
Relative sensitivities, specificities, and predictive values
for detection of plasma DNA and pp65 Ag were calculated
for both assays considering all specimens obtained from
patients with and without anti-CMV therapy at the time of
testing. Using as reference any positive test (either pp65
Ag or PCR assays), sensitivity/specificity/positive-predic-
tive-value/negative-predictive-value for detection of CMV
plasma DNA were 64%/100%/100%/94%, respectively.
Using as reference any positive test (either pp65 Ag or PCR
assays), sensitivity/specificity/positive-predictive-value/
negative-predictive-value for detection of pp65 Ag were
73%/100%/100%/95%, respectively.
Correlations between pp65 antigenemia and Cobas CMV 
PCR assays
To exclude any effect due to specific anti-CMV therapy,
correlation analysis of pp65 AG and PCR results was only
performed on 405 blood samples collected from patients
not on ganciclovir, foscarnet or cidofovir therapy; the
observed Kappa coefficient of agreement for both CMV
assays was 0.304 (poor agreement). The correlation for
both CMV assays were not significant among 43 out of
405 samples positive by both methods or by either meth-
ods (R2 = 0.000144, p = 0.94). On the contrary, when
both tests were positive, a significant correlation was
found (R2 = 0.68, p = 0.006) (FIG. 1). Plasma PCR assay
detected a median of 948 copies/ml (range 438–22600
copies/ml), while pp65 Ag assay showed a median of 6
positive cells/200000 PBL examined (range 1–400 cells).
Time to detection and disappearance of pp65 antigenemia 
and PCR in transplanted patients
Of the 38 patients, 28 (73.6%) developed positive pp65
Ag after a median of 41 days (range 0–100 days), while 15
(39.5%) developed a positive PCR after a median of 43
days (range 5–67 days) (p = 0.64, Student's t-test) from
SCT (Table 4). In 16 patients, CMV was first detected by
pp65 Ag alone (13 blood samples had 1 to 10 positive
pp65 Ag cells, 3 blood samples had 40, 32 and 20 positive
pp65 Ag cells, respectively), in 5 by both methods and in
6 by PCR assay alone (range 470–1710 copies/ml); one
patient had CMV biopsy-proven intestinal disease with-
out pp65 Ag and PCR assays positivity before CMV disease
(Table 3). The median time necessary to obtain a disap-
pearance of pp65 Ag and a negative PCR result was 7 days
(range 7–49 days) and 24 days (range 7–42 days), respec-
tively (p = 0.76) from the beginning of pre-emptive ther-
apy.
Incidence of positive pp65Ag and plasma PCR after SCT
For transplanted patients, the frequency to have a positive
pp65 Ag assay (28/38 patients, 73.6%) was significantly
higher than a positive PCR assay (15/38 patients, 39.4%)
(p = 0.003). When the type of transplant was analyzed,
the frequency to have a positive pp65 Ag assay (21/30
patients, 70%) was significantly higher than plasma PCR
assay (10/30 patients, 33.3%) (p = 0.013) in HLA-identi-
cal sibling, but was similar in unrelated donor transplant
(pp65 Ag positive in 7/8 patients, PCR positive in 5/8
patients) (p = 0.375). The frequency of CMV active infec-
tion was also similar between HLA-identical sibling trans-
plant recipients and unrelated donor transplant,
demonstrated by both the pp65 Ag assay (21/30 patients,
70% vs 7/8 patients, 87.5%), respectively, (p = 0.653) andBMC Infectious Diseases 2006, 6:167 http://www.biomedcentral.com/1471-2334/6/167
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Table 2: Patients with CMV infection
UPN ASSAY DAYS FROM TRANSPLANT
-7 0 +7 +14 +21 +28 +35 +42 +49 +56 +63 +70 +77 +84 +91 +100
0119.1 p p 6 5  A gN D N D N D-  •-  •-  • 1 • - - - -  •-  •-  •-  •-  • -  •
P l a s m a  P C R N D N D N D-  •-  •-  • -  • - - - -  •-  •-  •-  •-  • -  •
0120.1 pp65 Ag ND - • - • - • - • 7• - - †
Plasma PCR ND - • - • - • - • 970• - - †
0122.1 pp65 Ag - • - • NE - • - • - • - • 4• - - †
Plasma PCR - • - • - • - • - • - • - • - • - - †
0123.1 pp65 Ag - • - • - • - • - • - • - • 1• - - - - • - • - • - • - •
Plasma PCR - • - • - • - • - • - • - • - • - - - - • - • - • - • - •
0124.1 pp65 Ag - • - • - • - • - • 4• - - - - • 1• - - - - • - •
Plasma PCR - • - • - • - • - • - • - - - - • - • - - - - • - •
0125.1 pp65 Ag ND - • - • - • - • - • - • - • 7• - - - - • - • - • - •
Plasma PCR ND - • 770• - • - • - • - • - • - • - - - - • - • - • - •
5244.2 pp65 Ag - • - • NE - • - • - • 40• 2 80 7 - - - ND 2• -
Plasma PCR - • - • - • - • - • - • 1980• 1500 10000 1010 - - - ND - • -
0127.1 pp65 Ag NE NE NE NE NE - • - • 20• - - - - • - • - • - • - •
Plasma PCR - • - • - • - • - • - • - • - • 948 - - - • - • - • - • - •
0128.1 p p 6 5  A g -  •-  •N E-  •-  •-  • 5 • - - - -  •-  •-  •-  •-  • -  •
Plasma PCR - • - • - • - • - • - • - • - - ND - • - • - • - • - • - •
0130.1 pp65 Ag - • 5• - - - - • - • - • ND - • 1• - - - - • - •
Plasma PCR - • -• - - - - • - • - • ND - • - • - - - - • - •
0134.1 pp65 Ag - • - • NE NE - • - • 40• 6 2 - - - - • - • 8• -
Plasma PCR - • - • - • - • - • - • - • - - - - - - • - • - • -
0135.1 pp65 Ag - • - • NE - • - • - • - • 1• - - - - • - • - • - • - •
Plasma PCR - • - • - • - • - • - • - • - • - - - - • - • - • - • - •
0137.1 pp65 Ag - • - • NE - • - • - • - • - • 5• - - - - • - • - • - •
Plasma PCR - • - • - • - • - • - • - • - • - • - - - - • - • - • - •
0139.1 pp65 Ag - • ND - • - • - • - • - • 74• 30 6 - - - ND - • - •
Plasma PCR - • ND - • - • - • - • - • 6490
•
22400 9690 - - - ND - • - •
5224.2 pp65 Ag - • - • - • - • - • - • - • 30• - 5 - - 2 - - -
Plasma PCR - • - • - • - • - • - • 550• - • - 825 - - - - - -
5298.1 pp65 Ag - • - • - • - • - • - • - • - • 2• - - - - • - • - • ND
Plasma PCR - • - • - • - • - • - • - • - • - • - - - - • - • - • ND
5176.1 pp65 Ag - • - • - • - • - • - • - • - • - • 60• - - ND - • - • - •
Plasma PCR - • - • - • - • - • - • - • 470• 3830• NE 140
0
- ND - • - • - •
0149.1 pp65 Ag - • - • NE - • - • - • - • - • - • - • - • - • 2• - NE -
Plasma PCR - • - • - - • - • - • - • - • - • - • - • - • - - - -
0150.1 pp65 Ag - • - • - • - • - • - • - • - • 10• 4 - - - - • - • - •
Plasma PCR - • - • - • - • - • - • - • - • - • 832 153
0
680 - - • - • - •
0151.1 pp65 Ag - • - • - • - • - • 5• 3 - 1 - - - - • - • - • - •
Plasma PCR - • - • - • - • - • 438• - 695 - - - - - • - • - • - •
0152.1 pp65 Ag - • - • NE ND 32• - 144 - 13 30 3 - - - - • 422•
Plasma PCR - • - • - • ND - • 568 8960 955 2670 1720 111
10
307
0
125
0
659 - • 21200
•
0155.1 pp65 Ag - • - • - • NE - • - • ND - • - • - • - • 351• 9 - - -
Plasma PCR - • - • - • - • - • - • - • 463• 7860• 6510
•
126
00•
679
0•
477
0
-- -
0164.1 pp65 Ag - • - • NE NE - • - • - • - • 400• 4 7 - - - - • - •
Plasma PCR - • - • - • - • - • - • - • 891• 8280• 5830 736
0
--- -  • -  •
5278.2 p p 6 5  A g -  •-  •N EN E-  •1 • 1 - - - -  •-  •-  •-  •-  • -  •
Plasma PCR - • - • - • - • - • - • - - - - - • - • - • - • - • - •
0173.1 pp65 Ag NE NE NE - • - • - • ND - • - • - • - • 2• - - - - •
Plasma PCR - • - • - • ND - • - • - • - • - • - • 171
0•
152
0•
- - ND - •
UPN: unique patient number; Ag: antigenemia; PCR: polymerase chain reaction; ND: not done; NE: not evaluate; -: negative result; Ag and PCR 
values are expressed as N° of positive leucocytes or viral copies, respectively; †: death. Dots represent samples of patients not on pre-emptive 
therapyBMC Infectious Diseases 2006, 6:167 http://www.biomedcentral.com/1471-2334/6/167
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PCR assay (10/30 patients, 33.3% vs 5/8 patients, 62.5%),
respectively (p = 0.223).
When the incidence of CMV reactivation was analyzed
according to the severity of acute GVHD, patients with
grade II–IV acute GVHD developed CMV infection at a fre-
quency similar to those with grade 0–1 acute GVHD. The
frequency of positive pp65 Ag was 63.6% in 11 patients
with grade II–IV acute GVHD and 77.7% in 27 patients
with grade 0–I acute GVHD (p = 0.62). Similarly, the fre-
quency of positive PCR was 36.4% in 11 patients with
grade II–IV acute GHVD and 40.7% in 27 patients with
grade 0–1 acute GVHD (p = 0.99).
No differences between positive pp65 Ag and plasma PCR
assays were also found when patients were evaluated
according to the dose of acyclovir. The frequency of posi-
tive pp65Ag was 72.4% in 29 patients who received acy-
clovir at standard dose and 77.8% in 9 patients who
received acyclovir at high dose (p = 0.90). Similarly, the
frequency of positive plasma PCR assay was 34.5% in 29
patients who received acyclovir at standard dose and
55.5% in 9 patients who received acyclovir at high dose (p
= 0.43).
Patients with CMV diseases
Three patients developed intestinal CMV disease (7.9%):
of these, one had negative pp65Ag and PCR assays before
CMV disease, one had a concomitant positivity of both
methods (400 Ag positive cells and 22600 copies/ml) and
in the remaining patient only pp65 Ag was positive (7
positive cells) 1 week before the onset of CMV disease
(Table 3).
The UPN 0136.1 patient (Table 3) was diagnosed of renal
cancer on December 2002. The disease relapsed on May
2003 and the patient underwent allogeneic bone marrow
transplantation on September 2003. Conditioning regi-
men included total body irradiation and fludarabine.
GVHD prophylaxis was based on mycophenolate mofet-
ile and cyclosporine. On day 39, the patient developed a
grade II acute GVHD (skin) and therapy with prednisone
2 mg/kg/day was given. During the steroid treatment the
patient developed diarrhoea and was admitted to hospital
in the suspect of intestinal GVHD. On day 49, pp65AG
(400 cells)and PCR (22600 copies/ml) on blood sample
were positive. A colonoscopy demonstrated an hemor-
rhagic enterocolitis with viral inclusions in intestinal cells;
immunohistochemical analysis was positive for CMV. The
patient was diagnosed of CMV enteritis and therapy with
intravenous ganciclovir 10 mg/kg per day was adminis-
tered. In the following 4–6 weeks, pp65Ag and CMV DNA
decreased (Table 3); nevertheless, there was no resolution
shows on a logarithmic graph the correlation of CMV quanti- tation by CMV pp65 antigenemia and plasma PCR among 8  samples obtained from patients not on CMV treatment  determined positive by both methods (R2 = 0.68, P = 0.006) Figure 1
shows on a logarithmic graph the correlation of CMV quanti-
tation by CMV pp65 antigenemia and plasma PCR among 8 
samples obtained from patients not on CMV treatment 
determined positive by both methods (R2 = 0.68, P = 0.006).
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Table 3: Patients with CMV disease
UPN ASSAY DAYS FROM TRANSPLANT
-7 0 +7 +14 +21 +28 +35 +42 +49 +56 +63 +70 +77 +84 +91 +100
0133.1 Pp65 Ag - • - • - • ND - • - • - • - • - • -** • - - - - - 2
Plasma PCR - • - • - • ND - • - • - • - • - • -** • - - - - - -
0136.1 pp65 Ag - • - • - • - • - • - • - • - • 400** • 83 1 5 2 - 4 -
Plasma PCR - • - • - • - • - • - • - • - • 22600** • 12300 8810 6000 1290 - - -
0138.1 pp65 Ag - • - • - • 7• -** - - - • 60- • 23 4 - - - - 19
Plasma PCR - • - • - • - • -** - - - •- 1230- • 4070 16700 2240 - - 758 2250
UPN: unique patient number; Ag: antigenemia; PCR: polymerase chain reaction; ND: not done; NE: not evaluate; -: negative result; **: CMV disease. 
Dots represent samples of patients not on pre-emptive therapy.
All patients developed intestinal CMV disease and UPN 0136.1 died on day + 111 for CMV disease associated with aGVHD.BMC Infectious Diseases 2006, 6:167 http://www.biomedcentral.com/1471-2334/6/167
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of intestinal symptoms. The patient died for CMV disease
associated with acute GVHD on day 111.
The UPN 0138.1 patient (Table 3) was diagnosed of phil-
adelphia positive lymphoblastic leukemia on March
2002. On August 2003, the patient relapsed and under-
went an unrelated donor bone marrow transplantation on
November 2003. On day 14 after transplant, pp65AG was
positive (7 cells), while plasma PCR was negative and
therapy with foscarnet 180 mg/Kg/day was administered.
Because of diarrhea, a colonoscopy was performed. By an
intestinal biopsy, there was the evidence of viral inclu-
sions, and the immumnohistochemical analysis was pos-
itive for CMV. Foscarnet was switched to intravenous
ganciclovir because of renal failure. There was a rapid res-
olution of diarrhoea and the pp65AG was negative after
the first week of treatment. On day 42, ganciclovir was
stopped and the patient was discharged with oral acyclo-
vir. One week later the patient had a positivity of both
methods (pp65Ag:60 cells, plasma PCR:1230 copies/ml)
for CMV without gastrointestinal symptoms. Therapy
with ganciclovir was re-started, a progressive reduction of
pp65 Ag (Table 3) and a relevant increase of CMV DNA
(Table 2) were observed in the following weeks. The com-
plete clearance of both pp65Ag and plasma PCR was
observed following day+100. The patient died on May
2004 for JC virus leucoencephalitis.
The UPN 0133.1 patient (Table 3) underwent allogeneic
bone marrow transplantation for multiple myeloma. On
day 56, the patient developed diarrhoea, both pp65Ag
and plasma PCR were negative. Intestinal biopsy was pos-
itive for nuclear inclusions and immunohistochemical
analysis was positive for CMV. The patient started therapy
with foscarnet 180 mg/kg/day with resolution of intesti-
nal symptoms. Foscarnet was stopped on day 77. On day
100, only pp65Ag assay (2 cells) was positive and the
patient did not complain any intestinal symptoms. Ther-
apy with intravenous ganciclovir was started with disap-
pearance of pp65Ag.
Discussion
Despite major advances in treatment and prevention,
CMV infections remain an important cause of morbidity
and mortality in SCT recipients. Prophylaxis with ganci-
clovir during the first 100 days after transplantation
results effective in preventing CMV disease in high risk
patients, but is also associated with significant myelotox-
icity, increased incidence of invasive fungal infection, and
late CMV disease due to delayed CMV-specific T-cell
response recovery [10,29,30]. Ganciclovir or foscarnet
given pre-emptively to patients with documented active
CMV infection (positive pp65 Ag and/or PCR), can spare
a significant proportion of the population undergoing
SCT from exposure to potentially toxic antiviral therapy.
Therefore, a sensitive diagnostic test that reflects an active
CMV infection, such as pp65 Ag assay, is essential for the
success of pre-emptive therapy. In fact, using a pre-emp-
tive strategy based on a low threshold for the pp65 Ag
assay (any positive result) followed by a long ganciclovir
therapy (until day 100 post-SCT), the incidence of early
CMV disease was reduced to 3.8% [11], compared to 14%
found in a different study using a cut-off value of three
positive cells per 300.000 PBL examined [10]. In our
study, the pp65 Ag-guided strategy for the initiating of
pre-emptive therapy (any positive result) resulted in an
incidence of CMV disease before day +100 of 7.8%, rate
comparable to the recently reported incidences ranging
from 0 to 16% [10,11,14,25]. Furthermore, our pp65 Ag-
guided pre-emptive therapy, resulted in low frequencies of
secondary episodes of active CMV infection (Table 2, 3)
and zero episodes of late CMV disease were documented.
In our study, we prospectively compared the results of
plasma PCR and pp65 Ag assay; two commercially availa-
ble detection assays to monitor CMV infections in SCT
recipients receiving a pre-emptive antiviral therapy initi-
ated because of a positive pp65 Ag assay result. A clinical
finding of our study is the slight earlier positivity,
although not statistically significant, of pp65 Ag assay
over quantitative plasma PCR assay, finding in agreement
to those already reported by Boeckh et al. [25] and Boivin
et al. [31]. An earlier study suggested that detection of
CMV DNA in plasma might be equivalent to detection of
CMV by pp65 Ag [21]. In the present study, however,
despite the overall high sensitivity [17-21], PCR assay was
not positive in all blood samples that were found to be
positive by the pp65 Ag assay (Table 2, 3). Our study was
not designed to compare plasma PCR vs pp65 Ag as the
best parameter for starting pre-emptive therapy; therefore,
Table 4: Interval from transplantation to detection of first positive CMV test of samples from 38 SCT transplant recipient
Test method No. positive/total (% positive) Time (days to positivity)
Mean Median Range SD
Pp65 antigenemia 28/38 (73.7) 42.93 41 0–100 20.06
Plasma PCR 15/38 (39.5) 40.20 43 5–67 14.49BMC Infectious Diseases 2006, 6:167 http://www.biomedcentral.com/1471-2334/6/167
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no conclusions can be made on the clinical sensitivity of
PCR assay, since pre-emptive therapy was based on
pp65Ag assay.
Discordances between the positivity rates of the two
assays were found in our study. This discrepancy may be
explained: 1) by the choice of pp65 Ag assay for guiding
antiviral therapy, which may have modified CMV viral
load to be detected by plasma PCR; 2) the two methods
target different markers of virus replication, detecting free
virions in plasma and virus protein in PBL, with different
levels of sensitivity [17-21]. In addition, most of the sam-
ples with discordant results were found to be pp65 Ag
positive and plasma PCR negative. Our data are in agree-
ment with those reported by Boivin et al. [31] and by
Boeckh et al. [25], but are discrepant with those reported
by Solano et al. [17]. The reasons for such a discrepancy
are not clear since the protocol used to perform pp65Ag
assay and the type of PCR appeared not to be substantially
different from that followed in our study. However, diag-
nosis based on molecular methods for early detection of
CMV DNAemia in solid organ transplant [32,33] and in
bone marrow recipients [34] appears to correlate better
with active viral replication and with prediction of CMV
disease than pp65AG. However, it should be mentioned,
that, CMV disease may still develop in patients who have
negative pp65AG or undetectable DNA [1].
Because a low CMV viral load is highly significant in the
context of SCT, the primary objective should be on
improving sensitivity [26,35]. Therefore, when in our
study detection of ≥1 antigen positive cell and ≥400 CMV
DNA copies/ml (lower detection limit of Cobas Amplicor
CMV Monitor test) were defined as positive results, the
pp65Ag assay showed 73%/100%/100%/95%, for sensi-
tivity/specificity/positive predictive value/negative predic-
tive value, using any positive test (either pp65 Ag or PCR
assays) as the reference. Boeckh et al [25] demonstrated
that detection of CMV DNA in PBL by PCR was the most
sensitive method, followed by the pp65Ag assay, detec-
tion of CMV DNA in plasma and viremia. Their antigene-
mia assay showed 62%/88%/45%/94% for sensitivity/
specificity/positive predictive value/negative predictive
value, using plasma PCR as the reference. Yakushiji et al.
[36] compared the results of pp65 Ag assay with those
obtained by plasma real-time PCR; the pp65 Ag assay
showed a sensitivity of 55.4% and a specificity of 95.5%
using the real-time PCR as the reference. The sensitivity of
our pp65 Ag assay was similar to those obtained by
Boeckh et al [25], Boivin et al [31], and Yakushiji al. [36].
As the pp65Ag assay was found to be positive earlier than
PCR, it became negative faster after initiation of antiviral
therapy, although these differences did not reach statisti-
cal significance. The finding of faster clearance of pp65 Ag
compared to plasma CMV DNA after treatment has been
observed in the context of SCT [17,31]; it is interesting to
note that patients who continued to be plasma CMV DNA
positive after conversion of the pp65Ag (from positive to
negative result) did not progress to CMV disease. There-
fore, pp65Ag assay is suitable for monitoring the efficacy
of anti-CMV therapy.
In particular, the kinetics of pp65AG and plasma DNA
assays in a patient with CMV disease (UPN 0.138.1)
(Table 3), show a disconnection between pp65Ag and
PCR as the pp65Ag values are decreasing (from 60 to 4
cells) from days +49 to +63 while CMV DNA (from 1230
to 16700 copies/ml) is actually increasing. After 10 weeks
of ganciclovir therapy the patient recovered from CMV
infection. We have not a definitive explanation for this
phenomenon.
In our study, the probability of patients to have a pp65 Ag
positive assay was higher than to have a PCR positive
assay. When we analyzed this finding, pp65 Ag positive
result was statistically more frequent than PCR result in
patients receiving an HLA-identical sibling transplant.
However, 11 of these 21 patients had a positivity only for
pp65 Ag with a low level of positive cells (median 2 posi-
tive cells, range 1–5). This suggests a CMV late phagocyto-
sis by PBL, despite the absence of virus replication [37].
Interestingly, a trend of more frequent CMV infection
(either pp65 Ag assay or PCR assay) was shown in unre-
lated donor transplant recipients than HLA-identical sib-
ling patients, while patients with acute GVHD II–IV grade
did not develop more CMV infection than those with
grade 0–1 acute GVHD. These findings could be explained
by the lower number of unrelated patients compared to
related who entered in our study. Further, in our study,
statistical analyses may be influenced by the small
number of patients, by the preexisting heterogeneity of
conditioning regimens, GVHD prophylaxis, hematologi-
cal diseases and donor type.
The choice of the ideal sample material for PCR (plasma,
serum, leukocytes, or whole blood), remains to be eluci-
dated. Furthermore, viral loads obtained in whole blood,
where higher than those measured in plasma, serum, PBL
and peripheral blood mononuclear cells [21]. Although
the use of plasma may lead to a loss of sensitivity as com-
pared with leukocytes, it detects only free virions indica-
tive of active viral replication with a higher clinical
relevance [1,23,24]. Thus, it could minimize over-treat-
ment and discriminate between active infection and latent
infection. Although comparative results of different meth-
ods and samples materials have been reported, it seems
difficult to draw definitive conclusions as these different
methods have been evaluated in different patient popula-BMC Infectious Diseases 2006, 6:167 http://www.biomedcentral.com/1471-2334/6/167
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tion (recipients of SCT or solid organ transplant, acquired
immunodeficiency syndrome) [15,21,23,24,38], as well
as the choice of primers may also influence the sensitivity
of PCR. Recently, Boeckh M et al [39] developed a highly
sensitive quantitative plasma PCR assay using two primers
(UL55/UL123-exon 4); this assay was more sensitive than
pp65 Ag assay and single-primer plasma PCR assays
(UL125 alone, UL126 alone).
Conclusion
Both pp65Ag and quantitative plasma PCR assays
(COBAS AMPLICOR CMV MONITOR) are useful in early
detection of CMV infection and prevention of CMV dis-
ease after allogeneic SCT. Moreover, in the three patients
who developed CMV disease, PCR anticipated the onset of
CMV disease in one patient, while pp65 Ag in two, show-
ing that both tests are useful in diagnosing CMV diseases.
Lower thresholds should be probably adopted for quanti-
tative assays in the context of SCT, because small amounts
of CMV load require immediate therapy. Therefore, fur-
ther studies are required to determine the diagnostic value
of each method to guide pre-emptive therapy by the most
clinically suitable method in SCT recipients.
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